Nivolumab + Ibrutinib for CNS Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial studies the side effects and how well nivolumab and ibrutinib works in treating patients with central nervous system lymphoma that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and ibrutinib may work better in treating patients with central nervous system lymphoma.
Who Is on the Research Team?
Jason Westin
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults with relapsed or refractory central nervous system lymphoma. Participants must have adequate organ function, not be pregnant or breastfeeding, agree to use effective contraception, and have had at least one prior systemic therapy. Excluded are those with uncontrolled conditions like hypertension, infections, certain cardiovascular diseases, autoimmune diseases, recent major surgeries or therapies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive ibrutinib daily and nivolumab bi-weekly for up to 6 courses, each lasting 28 days
Extension
Patients achieving at least a partial response may continue therapy for up to 2 years
Follow-up
Participants are monitored for safety and effectiveness after treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Ibrutinib
- Nivolumab
Ibrutinib is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator